Clinical Trial Update: Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating arsenic trioxide in patients with refractory solid tumors possessing rescuable p53 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: Ruijin Hospital | Conditions: Refractory Solid Tumors | Phase 2 | Status: UNKNOWN